ScreenerHero

VYGR Voyager Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · voyagertherapeutics.com
2.470USD+0.41%Mkt Cap: 152.20M $P/E: —

Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibod…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap152.20M USD
Enterprise Value67.81M USD
Revenue (TTM)34.46M USD
Gross Profit-81.60M USD
Net Income (TTM)-119.72M USD
Revenue/Share0.58 USD
Last Price2.470 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees141
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.92
PEG—
EV/EBITDA-0.62
EV/Revenue1.97
P/S4.40
P/B0.98
EPS (TTM)-1.81
EPS (Forward)-1.28
52W Range
2.3903% of range5.550
52W High5.550 USD
52W Low2.390 USD
Profitability
Gross Margin-236.81%
Oper. Margin-833.87%
EBITDA Margin0.00%
Profit Margin-296.53%
ROE-61.06%
ROA-47.46%
Growth
Revenue Growth-39.10%
Earnings Growth—
Cash Flow & Leverage
Operating CF-132.47M USD
CapEx (TTM)2.60M USD
FCF Margin-224.35%
FCF Yield-50.80%
Net Debt-83.77M USD
Net Debt/EBITDA0.76
Balance Sheet
Debt/Equity0.19
Current Ratio7.50
Quick Ratio7.16
Book Value/Sh2.52 USD
Cash/Share1.89 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)14.89 USD
Upside (mean)+502.8%
Target Range8.000 USD – 25.00 USD
8.000+502.8% to mean25.00
# Analysts9
Ownership
Shares Out.61.62M
Float44.47M
Insiders14.84%
Institutions57.87%
Short Interest
Short Ratio8.5d
Short % Float6.94%
Short % Out.5.93%
Shares Short3.66M
Short (prev mo.)3.95M
Technical
SMA 503.140 (-21.3%)
SMA 2003.649 (-32.3%)
Beta1.28
S&P 52W Chg16.45%
Avg Vol (30d)563.71K
Avg Vol (10d)787.38K
Technical Indicators
RSI (14)25.8
MACD-0.2144
MACD Signal-0.1687
MACD Hist.-0.0458
BB Upper3.572 USD
BB Middle2.897 USD
BB Lower2.221 USD
BB Width46.63%
ATR (14)0.1486 USD
Vol Ratio (20d)1.21x